GKOSNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
GLAUKOS Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$166.96+2.12 (+1.29%)
Close on Oct 19, 2026
- Market cap
- $9.82B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Gross margin
55.7%−3.5 pts over 5 years
Operating margin
-39.3%+15.6 pts over 5 years
Net margin
-37.0%+16.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +32.3% | +21.5% | +17.7% | +21.6% | |
| Gross profit | -2.3% | +9.8% | +16.2% | +17.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 4.3% | -18.0% | -26.4% | |
| Return on assets | 3.6% | -13.2% | -20.1% | |
| Current ratio | 7.09 | 9.45 | 4.69 | |
| Interest coverage | – | -8.8× | -43.1× | |
| Inventory turnover | 3.0× | 3.1× | 3.7× | |
| Capex to revenue | 5.5% | 3.1% | 1.5% | |
| Diluted shares | 36M | 44M | 57M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Glaukos generated $191.66M from operations and spent $112.26M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$191.66M
Used
$112.26M
Capital expenditure$112.26M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-37.0%
×Asset turnover0.54×
×Equity multiplier1.31×
=Return on equity, FY2025-26.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -37.0% | 0.54× | 1.31× | -26.4% |
| FY2024 | -38.2% | 0.40× | 1.56× | -23.8% |
| FY2023 | -42.8% | 0.32× | 1.96× | -27.2% |
| FY2022 | -35.1% | 0.28× | 1.84× | -17.8% |
| FY2021 | -16.9% | 0.29× | 1.64× | -7.9% |
| FY2020 | -53.5% | 0.25× | 1.36× | -18.0% |
| FY2019 | 6.5% | 0.46× | 1.21× | 3.6% |
| FY2018 | -7.1% | 0.97× | 1.19× | -8.3% |
| FY2017 | -0.1% | 1.06× | 1.18× | -0.1% |
| FY2016 | 4.0% | 0.91× | 1.18× | 4.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$187.69M
- Cash generatingOperating cash flow above zero-$14.79M
- Return on assets improvedROA up on the prior year-15.6% → -19.3%
- Earnings backed by cashOperating cash flow above net income-$14.79M vs -$187.69M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.99 → 4.69
- No dilutionShare count did not rise53M → 57M
- Gross margin improvedGross margin up on the prior year75.48% → 55.72%
- More efficientAsset turnover rose0.41 → 0.52